---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-064341"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:16:03.972153+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR/VERTEX get UK conditional approval for CASGEVY in sickle cell & beta thalassemia

## Summary
- CASGEVY (exagamglogene autotemcel) received conditional marketing authorization from UK MHRA.
- Approved for patients 12+ with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
- Authorization requires no human leukocyte antigen matched related donor; valid for one year, renewable annually.
- CRISPR and partner Vertex jointly developed the CRISPR/Cas9 gene-edited therapy.

## SEC filing metadata
- accession: 0000950170-23-064341
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023064341/0000950170-23-064341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023064341/crsp-20231115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-064341
- JSON: https://secwatch.observer/filing/0000950170-23-064341.json
- Plain text: https://secwatch.observer/filing/0000950170-23-064341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.